January 13, 2010 (Miami, Florida) — Aerosolized bronchodilators are independently associated with an increased risk for ventilator-associated pneumonia (VAP) in critically ill patients, according to ...

NEW ORLEANS — Use of spirometry with bronchodilator testing can help reduce overdiagnosis of COPD as well as help differentiate COPD from asthma and asthma-COPD overlap syndrome, researchers reported ...

A retrospective cohort study of <29-week-gestation infants with evolving BPD defined at age 28 days within the Pediatric Health Information System database. Controlling for observed confounding with ...

A study of Korean patients with chronic obstructive pulmonary disease (COPD) found that a paradoxical response to short-acting bronchodilators may reduce lung function and quality of life. The study ...

Although there is significant improvement in managing asthma and chronic obstructive pulmonary disease (COPD) diseases, there is still a strong need in controlling symptoms to prevent hospitalizations ...

Researchers find a 28 percent greater risk of heart attack and stroke in older patients taking commonly prescribed drugs for chronic obstructive pulmonary disease (COPD). Canadian scientists are ...

And compared with the rest of the year, bronchodilator responsiveness was more common in winter months. HealthDay News — Patients are more likely to have positive bronchodilator responsiveness in the ...

Please provide your email address to receive an email when new articles are posted on . Spirometry testing in the afternoon vs. morning was linked to a decreased likelihood for bronchodilator ...

Eighteen RCTs with a total of 6086 patients were included in the analysis. For patients with moderate to severe chronic obstructive pulmonary disease (COPD), dual bronchodilator therapy with a ...

Novartis' dual combination bronchodilator Utibron Neohaler inhalation powder for patients with chronic obstructive pulmonary disease (COPD) has received FDA approval. It is not indicated to treat ...

Little evidence exists to support the widespread use of bronchodilators to treat children and adults with cystic fibrosis, according to a new systematic review of published research. Little evidence ...

July 1, 2011 (UPDATED July 21, 2011) — The US Food and Drug Administration (FDA) approved a once-daily bronchodilator — indacaterol maleate (Arcapta Neohaler, Novartis Pharmaceuticals) — for chronic ...